Search

Your search keyword '"Gentile M."' showing total 95 results

Search Constraints

Start Over You searched for: Author "Gentile M." Remove constraint Author: "Gentile M." Database OAIster Remove constraint Database: OAIster
95 results on '"Gentile M."'

Search Results

1. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study

2. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort

3. Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19

4. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV

5. Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study

6. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

7. The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

8. Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort

9. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

10. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study

11. Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study

12. Management of intracranial hypertension following traumatic brain injury: A best clinical practice adoption proposal for intracranial pressure monitoring and decompressive craniectomy: Joint statements by the Traumatic Brain Injury Section of the Italian Society of Neurosurgery (SINch) and the Neuroanesthesia and Neurocritical Care Study Group of the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI)

13. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

14. Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib

15. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

16. Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

17. Adult phenotype in Koolen-de Vries/KANSL1 haploinsufficiency syndrome

18. How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia

19. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

20. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

21. Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study

22. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?

24. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV

25. Data and optimisation requirements for Kidney Exchange Programs

26. Clinical Features of Patients with Cervical Artery Dissection and Fibromuscular Dysplasia

27. La formazione del capitale umano

28. Introduzione [a: Viaggio nelle character skills : persone, relazioni, valori]

29. Lo sviluppo delle competenze cognitive e non cognitive negli studenti trentini

30. La formazione del capitale umano

31. Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group

32. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases

33. Management of intracranial hypertension following traumatic brain injury: A best clinical practice adoption proposal for intracranial pressure monitoring and decompressive craniectomy: Joint statements by the Traumatic Brain Injury Section of the Italian Society of Neurosurgery (SINch) and the Neuroanesthesia and Neurocritical Care Study Group of the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI)

34. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report

35. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

36. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

37. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

38. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.

39. “More-than-viral” Eurasian geographies of the covid-19 pandemic: interconnections, inequalities, and geopolitics

40. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

41. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study

42. “More-than-viral” Eurasian geographies of the covid-19 pandemic: interconnections, inequalities, and geopolitics

43. Phytocomplex influences antimicrobial and health properties of concentrated glycerine macerates

44. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

45. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

46. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

47. CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression

48. Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report

49. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study

50. A serious game for training verbal resilience to doorstep scams

Catalog

Books, media, physical & digital resources